Transaction details
Thomas N. Bohjalian, a director at Healthcare Realty Trust Inc (NYSE:HR), acquired 10,000 shares of the company's common stock on March 6, 2026. The block of shares was purchased at prices ranging from $18.09 to $18.10, for a total transaction value of $180,900. After the trade, Bohjalian directly holds 85,520 shares of Healthcare Realty Trust.
Market context
The purchase occurred as the REIT's shares were trading close to their 52-week high of $18.97. Over the prior 12 months, the stock has risen roughly 18%.
Valuation and income profile
According to InvestingPro analysis cited in company commentary, Healthcare Realty Trust currently appears overvalued relative to its Fair Value. That same analysis notes the REIT's long-standing dividend record: the company has paid dividends for 34 consecutive years and offers a current yield of 5.2%. The REIT is characterized in the analysis as a $6.5 billion healthcare real estate investment trust, and the dividend yield is identified as a notable draw for income-focused investors.
Recent financial results and analyst response
Healthcare Realty Trust reported fourth-quarter 2025 results that outpaced analyst expectations. The company posted earnings per share of $0.04, compared with a consensus forecast of $0.002. Revenue for the quarter slightly exceeded projections. Funds from operations were reported at $0.40 per share for the fourth quarter, which aligned with expectations.
Following the results, Cantor Fitzgerald raised its price target for Healthcare Realty Trust from $19 to $21 and kept an Overweight rating on the stock. The firm cited improvements in the company’s process, personnel, earnings growth potential, and balance sheet in explaining its decision to increase the target price.
Investor takeaways
The insider purchase by a director, the earnings beat in the fourth quarter of 2025, and an unchanged FFO result together present a mix of signals for market participants. The director's acquisition increases his direct ownership, and the REIT's dividend history and yield continue to be highlighted as relevant to income-oriented investors. At the same time, third-party analysis flags valuation as a potential concern.
Note on limitations
Details above reflect the specific transaction, reported results for the fourth quarter of 2025, the InvestingPro valuation comment, and Cantor Fitzgerald's post-earnings action. Where information is limited in source disclosures, this report reflects only the facts explicitly presented.